Valsartan Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Glucose Metabolism
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial demonstrated that treatment with the angiotensin receptor blocker (ARB) valsartan for 5 years resulted in a relative reduction of 14% in the incidence of type 2 diabetes in subjects with impaired glucose metabolism (IGM). We investigated whether improvements in β-cell function and/or insulin sensitivity underlie these preventive effects of the ARB valsartan in the onset of type 2 diabetes. RESEARCH DESIGN AND METHODS: In this randomized controlled, double-blind, two-center study, the effects of 26 weeks of valsartan (320 mg daily; n = 40) or placebo (n = 39) on β-cell function and insulin sensitivity were assessed in subjects with impaired fasting glucose and/or impaired glucose tolerance, using a combined hyperinsulinemic-euglycemic and hyperglycemic clamp with subsequent arginine stimulation and a 2-h 75-g oral glucose tolerance test (OGTT). Treatment effects were analyzed using ANCOVA, adjusting for center, glucometabolic status, and sex. RESULTS: Valsartan increased first-phase (P = 0.028) and second-phase (P = 0.002) glucose-stimulated insulin secretion compared with placebo, whereas the enhanced arginine-stimulated insulin secretion was comparable between groups (P = 0.25). In addition, valsartan increased the OGTT-derived insulinogenic index (representing first-phase insulin secretion after an oral glucose load; P = 0.027). Clamp-derived insulin sensitivity was significantly increased with valsartan compared with placebo (P = 0.049). Valsartan treatment significantly decreased systolic and diastolic blood pressure compared with placebo (P < 0.001). BMI remained unchanged in both treatment groups (P = 0.89). CONCLUSIONS: Twenty-six weeks of valsartan treatment increased glucose-stimulated insulin release and insulin sensitivity in normotensive subjects with IGM. These findings may partly explain the beneficial effects of valsartan in the reduced incidence of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
Effect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660 · cited 1×
“More recently, the large-scaled, prospective Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial addressed the potential of the ARB valsartan to protect individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) against type 2 diabetes and cardiovasc…”
BackgroundWhy blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes
Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000160198.05416.72 · Cited by 293 · cited 1×
“Recent trials (5,6) have suggested that RAS inhibition with angiotensin II receptor blockers (ARBs) or ACE inhibitors may reduce the incidence of newonset type 2 diabetes.”
BackgroundRole of aldosterone and angiotensin II in insulin resistance: an update
Lastra‐Lastra, G., Sowers, J. R., Restrepo‐Erazo, K., Manrique‐Acevedo, C., & Lastra‐González, G. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03498.x · Cited by 90
Goossens, G. H., Blaak, E. E., Saris, W. H. M., & van Baak, M. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032053 · Cited by 84
Self-citation
Cited by
Seferovic, J. P., Claggett, B., Seidelmann, S. B., Seely, E. W., Packer, M., Zile, M. R., Rouleau, J. L., Swedberg, K., Lefkowitz, M., Shi, V. C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30087-6 · Cited by 352
The renin–angiotensin–aldosterone system and glucose homeostasis
Luther, J. M., & Brown, N. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.006 · Cited by 185
Modulation of glucose metabolism by the renin-angiotensin-aldosterone system
Favre, G. A., Esnault, V. L. M., & Van Obberghen, E. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2014 · Cited by 114
Effects of aldosterone on insulin sensitivity and secretion
Luther, J. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.08.016 · Cited by 114
Medications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100
Metadata
- Authors
- van der Zijl, N. J., Moors, C. C. M., Goossens, G. H., Hermans, M. M. H., Blaak, E. E., & Diamant, M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 845-851
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2044427396
- Cited by
- 94
- References
- 5
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.